Enterobacter infections

Suggested Alternatives for Differential Diagnosis Enterobacter infections, enterococcal infections, klebsiella infections, proteus infections, providencia infections, Pseudomonas aeruginosa infections, serratia, shigellosis, and streptococcus group B infections. 

Suggested Alternatives for Differential Diagnosis Enterobacter infections. 

The efficacy of florfenicol in vivo was determined by measuring the dose required to obtain values for protection from infection in 50% of the animals (PD q) against 10 chloramphenicol-resistant strains and two chloramphenicol-sensitive isolates. Florfenicol, chloramphenicol, and thiamphenicol were evaluated concurrendy against each strain. Against sensitive Enterobacter 50 subcutaneous and oral routes were similar for dorfenicol and... 

The sulfonamides are often used to control urinary tract infections caused by certain bacteria such as Escherichia coli, Staphylococcus aureus, and Klebsiella-Enterobacter. Mafenide (Sulfamylon) and silver sulfadiazine (Silvadene) are topical sulfonamides used in the treatment of second- and third-degree bums. Additional uses of the sulfonamides are given in the Summary Drug Table The Sulfonamides. 

Simmons,B. P. Gelfand,M. S. Haas, M. Metts,L. Ferguson, J. Enterobacter sakazakii infections in neonates associated with intrinsic contamination of a powdered infant formula. Infect. Control Hosp. Epidemiol. 1989,10, 398-401. 

Muytjens, H. L. Kollee, L. A. Enterobacter sakazakii meningitis in neonates Causative role of formula Pediatr. Infect. Dis. J. 1990, 9, 372-373. 

Suggested Alternatives for Differential Diagnosis Infections from other bacteria such as Enterobacter, E. coli, Klebsiella, Proteus, and Providencia, producing meningitis, pneumonia, or sepsis. 

The urinary pathogens in complicated or nosocomial infections may include E. coli, which accounts for less than 50% of these infections, Proteus spp., Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, staphylococci, and enterococci. Candida spp. have become common causes of urinary infection in the critically ill and chronically catheterized patient. 

Complicated intra-abdominal infections (used in combination with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter spec es, or Bacteroides fragilis. 

Lower respiratory tract infections - Staphylococcus aureus (penicillinase-producing), Escherichia coli, Klebsiella sp., Enterobacter sp., Haemophilus influenzae, Haemophilus parainfluenzae, Acinetobactersp., Serratia marcescens. 

Intra-abdominal Infections - Enterococcus faecalis, S. aureus (penicillinase-producing), Staphylococcus epidermidis, E. coli, Klebsiella sp., Enterobacter sp., Proteus sp., M. morganii, P. aeruginosa, Citrobactersp., Clostridium sp., Bacteroides sp. including Bacteroides fragilis, Fusobacterium sp. Peptococcus sp., Peptostreptococcus sp., Eubacterium sp., Proplonibacterium sp.. Bifidobacterium sp. 

Bone and joint infections - E. faecalis S. aureus (penicillinase-producing), S. epidermidis, Enterobacter sp., P. aeruginosa. 

Skin and skin structure infections- Skin and skin structure infections, including abscesses, cellulitis, infected skin ulcers, and wound infections caused by S. aureus (including penicillinase-producing strains) Streptococcus pyogenes, group D streptococcus including . faecalis, Acinetobacter sp. including iA. calcoaceticus] Citrobactersp.] E. coli] Enterobacter cloacae, K. pneumoniae]... 

Urinary tract infections Urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter sp., and Serratia marcescens. 

Gynecologic infections Gynecologic infections, including endometritis and pelvic cellulitis caused by E. coli, K. pneumoniae, Enterobacter sp. including . cloacae, and P. mirabilis. 

Urinary tract infections Nalidixic acid is indicated for the treatment of urinary tract infections (UTIs) caused by susceptible gram-negative microorganisms, including the majority of Escherichia coli, Enterobacter species, Klebsiella species, and Proteus species. Perform disc susceptibility testing with the 30 meg disc prior to administration of the drug and during treatment if clinical response warrants. 

Urinary tract infections (UTIs) For the treatment of UTIs when caused by susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. 

May be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially Enterobacter sp. and Escherichia coii. It usually is less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Consider using only when the more conventional therapy has failed and when the organism has demonstrated sensitivity. 

Local treatment of skin and soft tissue infections with antibiotic-containing ointments or solutions should not be used because it leads to allergic reactions and rapid development of bacterial resistance. In settings where MRSA or resistant Enterobacte-riaceae (like ESBL s gram negative bacteria with extended spectrum beta lactames) or Pseudomonas spp. occur, the empiric use of vancomycin and a carbapenem can be necessary. The risk of transmission of these organisms should be minimalised by hygienic and isolation measures. 

Used in all types of infection caused by Salmonella typhi, Klebsiella, Enterobacter, Pneumocystis carinii etc. and many other sulfonamide resistant stains of S. aureus, Strep, pyogenes, Shigella, E. coli, H. influenzae, meningococci and gonococci etc. It is particularly effective as a second line agent in penicillin allergic patients and also in patients where newer antibiotics are contraindicated or can t be used. 

---